LUNG CANCER
Tony S. K. Mok, MD
The Chinese University of Hong Kong
- Mok is the Li Shu Fan Professor of Clinical Oncology and chair of the Department of Clinical Oncology at The Chinese University of Hong Kong.
- He has led multiple multinational studies including IPASS, FASTACT-2, IMPRESS, ARCHER1050, ALEX, and AURA3 that have defined the current paradigm in management of EGFR-positive lung cancer. His leadership in the ALEX study helped establish a new paradigm by demonstrating that treatment with alectinib (Alecensa) resulted in significant improvement in progression-free survival.
- In the AURA3 trial, Mok and colleagues showed that patients with NSCLC who develop a T790M resistance mutation after receiving EGFR-targeted therapy can be treated with osimertinib (Tagrisso). The New England Journal of Medicine chose the article detailing the findings as 1 of its 10 most notable articles of 2017.
- He also has helped define the management of ALK-positive NSCLC, notably through the PROFILE 1014 trial, which demonstrated that crizotinib (Xalkori) was superior to chemotherapy for previously untreated patients with the alteration. In the
- Additionally, he led the KEYNOTE-042 trial, which showed that treatment with single-agent pembrolizumab (Keytruda) improved overall survival for patients with PD-L1–positive lung cancer. He is also leading other studies on immunotherapy including NEPTUNE, POSEIDON, and CheckMate722.
